Buy -- Price 3.54 on March 10 by Roth Capital Partners Shares now trade for four times [fiscal] "09 [earnings-per-share] estimates versus peers' 12 times; using the peer multiple [would value] AOB at 10 a share. We are confident AOB will benefit from China's health-care initiative ($124 billion/next three years). The shares [look] attractive ... given the modest valuation and growth potential of the business. Market cap: $277 million.

Buy -- Price 6.75 on March 10 by Jesup & Lamont Nuclear-waste remediator ES was formed by the purchase of the Clive, Utah landfill and execution of a rollup strategy to vertically integrate all aspects of the waste life-cycle. [That model, and ES's] dominant market position, pricing power and earnings visibility position it for growth, even in the current economic environment; $6.6 billion has been allocated for nuclear remediation under the American Recovery and Reinvestment Act.We [derive a] 13.50 target by applying an 8.5 times [earnings before interest, taxes, depreciation and amortization] multiple to our "10E [estimate]. Market cap: $596 million.

Buy -- Price 2.21 on March 10 by FTN Equity Capital Markets Enterprise agreed to purchase the "assets" of Advantage Rent-a-Car out of bankruptcy for roughly $19 million ... . We believe Enterprise's pending purchase was driven by expansion of current Enterprise brands, and to prevent HTZ from rolling out the Simply Wheelz [discount] offering into new markets. Industry contacts don't believe Enterprise will look to operate the Advantage brand over the long run [and don't] see the Enterprise acquisition ... as a signal of looming changes in the industry's competitive structure. Market cap: $817 million.

Market Perform/Speculative -- Price 25.73 on March 10 by Morgan Keegan MD is the U.S.'s leading provider of neonatal, maternal/fetal and pediatric-physician subspecialty and anesthesia services. We are lowering our estimated EPS to reflect potential crowd-out from recently enacted [State Children's Health Insurance Program] expansion and our concern that [neonatal intensive-care unit] volumes could weaken further, beginning the second quarter. Our revised 2009 E-EPS is $3.05, down from $3.21. Our revised 2010 estimate is $3.39 versus $3.47. [Yet] we view Mednax as well-run, with strong cash flows serving a business with good long-term growth dynamics. Market cap: $1.2 billion.

Buy -- Price 17.18 on March 10 by Morgan Joseph We call attention to Penn's 6.875% senior subordinated notes due 2011 and 6.75% senior subordinated notes due 2015 for risk-averse accounts ... . We believe Penn is well-positioned to increase Ebitda quickly when consumers decide to spend more, likely in FY10. We estimate revenue, Ebitda, and EPS of $2.5 billion, $668 million, and $1.58 in FY10 ... . With Penn's strong balance sheet, we think the shares should trade at 7 times; [applied to] our FY09 E-Ebitda of $616 million, it equates to a 25 target. Penn trades at 5.7 times our FY09 E-Ebitda and 4.8 times our FY10 estimate. Market cap: $1.8 billion.

Hold -- Price 26.11 on March 10 by Wedbush Morgan With minimal growth expected for this infrastructure-software provider in "09, and given its complex product portfolio, which has yet to generate meaningful synergies, we don't expect meaningful multiple-expansion. But we feel SY's high level of recurring revenue, strong operating margins and solid record of EPS outperformance should [bring the shares to] 29, or 12 times FY10 EPS, a slight premium to our forecast long-term EPS growth rate of 10%. Market cap: $2.2 billion.

Market Perform -- Price 12.58 on March 10 by Keefe, Bruyette & Woods Target: 16. USB reduced its quarterly dividend to five cents a share from 42.5 cents per share ... to save approximately $2.6 billion per year in equity. USB disclosed that the decision to cut the dividend was related to preservation of capital in a challenging environment and enhancement of its ability to pre-pay the [Troubled Asset Relief Program] capital. As a result of the higher-than-expected savings, our cycle-end, stress case [tangible-common-equity] ratio increased to 4.65% from 4.41%. Our analysis doesn't assume that USB requires additional capital based on its ability to generate capital in excess of its peers. In addition, management stated that quarter-to-date operating results have been relatively in line with previous guidance. Market cap: $22 billion.